This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ESMO 2019
ESMO 2019 Prostate Cancer
Conferences
ESMO 2019
Prostate Cancer
Kidney Cancer
Bladder Cancer
Testicular Cancer
ESMO 2019 Prostate Cancer
Viewing 41-60 of 138 articles
ESMO 2019: Erdatitinib versus Available Therapies in Advanced Urothelial Cancer: A Matching Adjusted Indirect Comparison
ESMO 2019: Hyperphosphatemia Due to Erdafitinib and Anti-tumor Activity Among Patients with Advanced Urothelial Cancer
ESMO 2019: Multiple-cohort Analysis Investigating FGFR3 Alteration as a Predictor of Non-response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer - A Medical Oncologist's Perspective
ESMO 2019: The Associated of CD8 Infiltration and PD-L1 Expression and Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab, NIVOREN GETUG-AFU 26 Translational Study
ESMO 2019: Phase 3 Trial of Adjuvant Sunitinib in Patients with High-risk Renal Cell Carcinoma: Comprehensive Tumor Genomic and Transcriptomic Analyses
ESMO 2019: Primary Renal Tumour Shrinkage in Patients who did not Undergo Upfront Cytoreductive Nephrectomy: Subgroup Analysis from Phase 3 JAVELIN Renal 101 Trial
ESMO 2019: Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus Axitinib Alone in Patients with Advanced or mRCC
ESMO 2019: Health-Related Quality of Life in a Randomized Phase 3 trial of Enzalutamide with Standard First Line Therapy for mHSPC: ENZAMET, an ANZUP-led, International, Co-Operative Group Trial - A Medical Oncologist's Perspective
ESMO 2019: Efficacy and Biomarker Analysis of Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: Subgroup Analysis from the Phase 3 JAVELIN Renal 101 Trial of First-line Avelumab Plus Axitinib vs Sunitinib
ESMO 2019: Patient-Reported Outcomes From TITAN in Patients with Metastatic Castration-Sensitive Prostate Cancer
ESMO 2019: Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer - NABUCCO
ESMO 2019: A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC
ESMO 2019: Phase 3 Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Comprehensive Tumor Genomic and Transcriptomic Analyses
ESMO 2019: Invited Discussant: Patient Reported Outcomes in Metastatic Hormone-Naïve Prostate Cancer and Who to Give Primary Radiotherapy To?
ESMO 2019: NIVOREN GETUG-AFU 26 Translational Study: CD8 Infiltration and PD-L1 Expression are Associated with Outcome in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab
ESMO 2019: Patient-Reported Outcomes From TITAN: A Phase 3, Randomized, Double-Blind Study of Apalutamide Versus Placebo Added to Androgen Deprivation Therapy in Patients With Metastatic Castration-Sensitive Prostate Cancer
ESMO 2019: FGFR3 Alteration as a Predictor of Non-Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
ESMO 2019: Exploratory Analyses of Metastatic Site and Number in the STAMPEDE “M1|RT Comparison”
ESMO 2019: Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries
ESMO 2019: Central, Prospective Detection of Homologous Recombination Repair Gene Mutations (HRRm) in Tumour Tissue from >4000 Men with mCRPC Screened for the PROfound Study
1
2
3
4
5
6
7
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free